This article highlights recent developments in healthcare, including the U.S. FDA's approval of Alzheimer's and diabetes ...
Prolonged rapid eye movement (REM) sleep latency was linked with Alzheimer's disease biomarkers, cross-sectional data showed.
The Phase III trial saw a clinically meaningful benefit in overall survival with a combination of Itovebi alongside Ibrance ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback